

# ANNOUNCEMENT OF ALLOTMENT RESULTS

## SUMMARY

### Offer Price

- The Offer Price has been determined at HK\$18.00 per Offer Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%).

### Net Proceeds from the Global Offering

- Based on the Offer Price of HK\$18.00 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of underwriting fees and commissions and estimated expenses payable by the Company in connection with the Global Offering is estimated to be approximately HK\$153.4 million, assuming the Over-allotment Option is not exercised. The Company intends to apply such net proceeds in accordance with the purposes as set out in the section headed “Net Proceeds from the Global Offering” in this announcement. In the event that the Over-allotment Option is exercised, the Company will apply the additional net proceeds to the purposes and in the proportions as set out in the paragraph headed “Net Proceeds from the Global Offering” in this announcement.
- If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of HK\$29.4 million for 1,794,200 Shares to be issued upon the exercise of the Over-allotment Option.

### Applications and Indications of Interest Received in the Hong Kong Public Offering

- The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been slightly over-subscribed. A total of 9,206 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and through the **CCASS E IPO** service for a total of 11,503,800 Hong Kong Offer Shares, representing approximately 9.62 times of the total number of 1,196,200 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.
- As the over-subscription of the Hong Kong Public Offering is less than 15 times of the number of Offer Shares initially available for subscription under the Hong Kong Public Offering, no reallocation procedures as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus has been applied. The final number of Hong Kong Offer Shares available under the Hong Kong Public Offering is 1,196,200 Shares, representing approximately 10% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), and being allocated to 2,197 successful applicants under the Hong Kong Public Offering.

## International Offering

- The Offer Shares initially offered under the International Placing have been oversubscribed, representing approximately 2.05 times of the total number of Offer Shares initially available under the International Offering. There is no reallocation of Offer Shares between the Hong Kong Public Offering and the International Offering and the final number of Offer Shares under the International Placing is 10,765,600 Shares, representing approximately 90% of the total number of Offer Shares under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 1,794,200 Offer Shares in the International Offering and there are a total of 140 placees under the International Offering.
- A total of 100 placees have been allotted five board lots of Offer Shares or less, representing approximately 71.43% of 140 placees under the International Offering. These placees have been allotted 22,600 Shares in total, representing approximately 0.21% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised). A total of 90 placees have been allotted one board lot of Offer Shares, representing approximately 64.29% of 140 placees under the International Offering. These placees have been allotted 18,000 Shares in total, representing approximately 0.17% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised).
- The International Offering is conducted in compliance with the Placing Guidelines for Equity Securities in Appendix 6 to the Listing Rules (the “**Placing Guidelines**”). The Directors confirm that save as disclosed in “International Offering – Placing of International Offer Shares with Consent under Paragraph 5(2) of Placing Guidelines” in this announcement, no International Offer Share has been allocated to the core connected persons of the Company, the Directors, the existing Shareholders or their respective close associates (whether in their own names or through nominees) or any other persons as described in paragraph 5 of the Placing Guidelines. None of the Sole Sponsor, the Sole Representative, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers and the Underwriters, their respective affiliate companies, and the connected clients (as defined in the Placing Guidelines) of the lead broker (as defined in the Placing Guidelines) or of any distributors (as defined in the Placing Guidelines) has taken up any Offer Share for its own benefits under the Global Offering.
- The Directors confirm that none of the placees under the International Offering was placed more than 10% of the enlarged issued share capital of the Company immediately after completion of the Global Offering. Accordingly, the Directors confirm that none of the placees will become a Substantial Shareholder of the Company after the completion of the Global Offering, and there will not be any new Substantial Shareholder of the Company immediately after completion of the Global Offering.

- To the best of the knowledge of the Directors, save as disclosed in “International Offering – Placing of International Offer Shares with Consent under Paragraph 5(2) of Placing Guidelines” in this announcement, (i) none of the Offer Shares subscribed for by the placees or the public has been financed directly or indirectly by any of the Directors, chief executive, Controlling Shareholders, Substantial Shareholders or existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the members of the public who or which have subscribed for the Offer Shares is accustomed to taking instructions from any of Directors, chief executive, Controlling Shareholders, Substantial Shareholders or existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in their names or otherwise held by them.

### **Cornerstone Investors**

- Based on the Offer Price of HK\$18.00 per Offer Share, and pursuant to the Cornerstone Investment Agreements with the Cornerstone Investors as set out in the section headed “Cornerstone Investors” in the Prospectus, the Cornerstone Investors have subscribed for a total of 9,692,800 Offer Shares, representing (a) approximately 4.05% of the Company’s issued share capital immediately following the completion of the Global Offering and (b) approximately 81.03% of the total number of Offer Shares under the Global Offering, in each case assuming the Over-allotment Option is not exercised. Please refer to the section headed “Cornerstone Investors” in the Prospectus and the paragraph headed “Cornerstone Investors” below for further details relating to the Cornerstone Investors.

### **Placing of International Offer Shares with Consent under Paragraph 5(2) of Placing Guidelines**

- The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and the consent under paragraph 5(2) of the Placing Guidelines, in connection with the placing of International Offer Shares to the placees set out in “International Offering – Placing of International Offer Shares with Consent under Paragraph 5(2) of Placing Guidelines” in this announcement.

## **Over-allotment Option**

- In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Sole Representative on behalf of the International Underwriters, at any time from the Listing Date to Friday, July 15, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 1,794,200 additional Offer Shares, representing approximately 15% of the initial number of Offer Shares to be offered in the Global Offering, at the Offer Price to cover over-allocations in the International Offering, if any. There has been an over-allocation of 1,794,200 Offer Shares in the International Offering and such over-allocation will be settled by using Shares to be borrowed under the Stock Borrowing Agreement between Infinite Galaxy Health Limited and the Stabilising Manager. Such borrowed Shares will be covered by exercising the Over-allotment Option in full or in part, or by making purchases in the secondary market at prices that do not exceed the Offer Price, or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Company's website at <https://www.megagenomics.cn/> and on the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk), respectively. As of the date of this announcement, the Over-allotment Option has not been exercised.

## **Lock-up Undertakings**

- Each of the Company, the Controlling Shareholders, the Warranting Shareholders, the Pre-IPO Investors and the Cornerstone Investors are subject to certain Lock-up Undertakings as set out in the paragraph headed "Lock-up Undertakings" in this announcement.

## **Results of Allocations**

- The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be available at the times and date and in the manner specified below:
  - in the announcement to be posted on the Company's website at <https://www.megagenomics.cn/> and the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk) by no later than 9:00 a.m. on Tuesday, June 21, 2022;
  - from the "IPO Results" function in the **IPO App** and the designated results of allocations website at [www.tricor.com.hk/ipo/result](http://www.tricor.com.hk/ipo/result) or [www.hkeipo.hk/IPOResult](http://www.hkeipo.hk/IPOResult) with a "search by ID" function on a 24-hour basis from 8:00 a.m. on Tuesday, June 21, 2022, to 12:00 midnight on Monday, June 27, 2022; and
  - from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Tuesday, June 21, 2022, to Friday, June 24, 2022 on a business day.

- This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **HK eIPO White Form**” in this announcement refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **electronic application instructions** to HKSCC via CCASS” in this announcement are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.
- Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **HK eIPO White Form**” and “Results of Applications Made by Giving **electronic application instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

### **Despatch/Collection of Share Certificates and Refund Monies**

- For each applicant applying for Hong Kong Offer Shares through the **HK eIPO White Form** service:
  - Applicants who applied for 1,000,000 Hong Kong Offer Shares or more through the **HK eIPO White Form** service and who have been successfully or partially successfully allocated Hong Kong Offer Shares and are eligible to collect Share certificates in person may collect Share certificates from the Hong Kong Branch Share Registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Tuesday, June 21, 2022, or such other place or date as notified by the Company in the newspapers as the date of despatch/collection of Share certificates/e-Auto Refund payment instructions/refund cheques.
  - Applicants who do not collect their Share certificate(s) personally within the time specified for collection, it/they will be sent to the address specified in the relevant application instructions by ordinary post at the own risk of the applicant(s).
  - Applicants who apply for less than 1,000,000 Hong Kong Offer Shares through the **HK eIPO White Form** service, the Share certificate(s) (where applicable) will be sent to the address specified in the relevant application instructions on or before Tuesday, June 21, 2022 by ordinary post at the own risk of the applicant(s).
  - Applicants who apply and pay the application monies from a single bank account, any refund monies will be despatched to that bank account in the form of e-Auto Refund payment instructions. Applicants who apply and pay the application monies from multiple bank accounts, any refund monies will be despatched to the address as specified in the relevant application instructions in the form of refund cheque(s) by ordinary post at the own risk of the applicant(s).

- For each applicant applying for Hong Kong Offer Shares via **electronic application instructions** to HKSCC:
  - For the purposes of allocating Hong Kong Offer Shares, HKSCC Nominees will not be treated as an applicant. Instead, each CCASS Participant who gives **electronic application instructions** or each person for whose benefit instructions are given will be treated as an applicant.
  - Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC via CCASS will have their Share certificates issued in the name of HKSCC Nominees Limited and deposited into CCASS for credit to their designated CCASS Participant's stock account or their CCASS Investor Participant's the stock accounts on Tuesday, June 21, 2022, or, on any other date determined by HKSCC or HKSCC Nominees.
  - Applicants should check the application results of CCASS Participants (and where the CCASS Participant is a broker or custodian, information relating to the relevant beneficial owner is included), the successful supplicants' Hong Kong identity card number/passport number or other identification code (Hong Kong business registration number for corporations) and the basis of allocations of the Hong Kong Public Offering in the manner specified in the paragraph headed "Results of Allocations" in this announcement published by the Company on Tuesday, June 21, 2022 and report any discrepancies to HKSCC before 5:00 p.m. on Tuesday, June 21, 2022 or such other date as determined by HKSCC or HKSCC Nominees.
  - Where the applicant who has instructed a broker or custodian to give **electronic application instructions** on his/its behalf of, the applicant could also check the number of Hong Kong Offer Shares allotted to him/it and the amount of refund monies (if any) payable to him/it with that broker or custodian.
  - Applicants who applied as a CCASS Investor Participant can check the number of Hong Kong Offer Shares allocated to them and the amount of refund monies (if any) payable to them via the **CCASS Phone System** and the **CCASS Internet System** (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time) on Tuesday, June 21, 2022.
  - Refund of the application monies (if any) in respect of wholly and partially unsuccessful applications and/or difference between the Offer Price and the maximum Offer Price per Offer Share initially paid on application (including brokerage, SFC transaction levy, the Stock Exchange trading fee and FRC transaction levy but without interest) will be credited to the applicants' designated bank account or the designated bank account of the applicants' broker or custodian on Tuesday, June 21, 2022.

## **Public Float**

- The Directors confirm that
  - (i) immediately following completion of the Global Offering (assuming no exercise of the Over-allotment Option), around 48.7% of the total number of issued Shares will be held by the public, in compliance with the requirement under Rule 8.08(1) of the Listing Rules;
  - (ii) the Shares will be held by at least 300 Shareholders at the time of Listing, in compliance with Rule 8.08(2) of the Listing Rules; and
  - (iii) the three largest public Shareholders will not hold more than 50% of the Shares held in public hands at the time of Listing, in compliance with Rule 8.08(3) of the Listing Rules.

## **Commencement of Dealings**

- Assuming the Global Offering becomes unconditional in all respects at or before 8:00 a.m. on Wednesday, June 22, 2022 (Hong Kong time), dealing in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, June 22, 2022 (Hong Kong time). The Shares will be traded in board lots of 200 Shares each. The stock code of the Shares is 6667.

**In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded and should exercise extreme caution when dealing in the Shares.**

## **OFFER PRICE**

The Offer Price has been determined at HK\$18.00 per Offer Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%).

## **NET PROCEEDS FROM THE GLOBAL OFFERING**

Based on the Offer Price of HK\$18.00 per Offer Share, the net proceeds from the Global Offering to be received by the Company after deduction of underwriting fees and expenses payable by the Company in connection with the Global Offering are estimated to be approximately HK\$153.4 million (assuming the Over-allotment Option is not exercised).

The Company intends to apply the net proceeds from the Global Offering as follows:

- (i) *Sales and Marketing.* Approximately 30%, or HK\$46.0 million will be allocated to the sales, marketing and commercialization of our consumer genetic testing and cancer screening services and products.
- (ii) *Research and Development.* Approximately 25%, or HK\$38.4 million, will be invested in research and development of our services and products.
- (iii) *Testing Capability and Capacity.* Approximately 20%, or HK\$30.7 million, will be allocated to increasing or expanding our testing capability and capacity.
- (iv) *Investment and Acquisitions.* Approximately 15%, or HK\$23.0 million, will be allocated to fund our expansion across the industry value chain by investing into or acquiring attractive technology or testing related companies that are complementary and synergistic with our existing businesses.
- (v) *Working Capital and Other Purposes.* Approximately 10%, or HK\$15.3 million is expected to be used for working capital and other general corporate purposes.

If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$29.4 million for 1,794,200 additional Offer Shares to be issued and allotted upon the exercise of the Over-allotment Option. In the event that the Over-allotment Option is exercised, the Company will apply the additional net proceeds to the purposes and in the proportions as set out in the paragraph headed “Net Proceeds from the Global Offering” in this announcement.

To the extent that our net proceeds are not sufficient to fund the purposes set out above, we intend to fund the balance through a variety of means, including cash generated from operations and other financing alternatives, if necessary.

To the extent that the net proceeds are not immediately required for the above purposes and to the extent permitted by the relevant law and regulations, we will deposit such funds as short-term deposits in licensed banks or financial institutions only.

For further information, please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.

## APPLICATIONS AND INDICATIONS OF INTEREST RECEIVED IN THE HONG KONG PUBLIC OFFERING

The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been slightly over-subscribed. A total of 9,206 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and through the **CCASS EIPO** service for a total of 11,503,800 Hong Kong Offer Shares, representing approximately 9.62 times of the total number of 1,196,200 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.

- As the over-subscription of the Hong Kong Public Offering is less than 15 times of the number of Offer Shares initially available for subscription under the Hong Kong Public Offering, no reallocation procedures as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus has been applied. The final number of Hong Kong Offer Shares available under the Hong Kong Public Offering is 1,196,200 Shares, representing approximately 10% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), and being allocated to 2,197 successful applicants under the Hong Kong Public Offering, among which:
  - 9,203 valid applications in respect of a total of 10,603,800 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$18.00 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) of HK\$5 million or less, representing approximately 17.73 times of the 598,200 Hong Kong Offer Shares initially comprised in pool A; and
  - 3 valid applications in respect of a total of 900,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$18.00 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) of more than HK\$5 million, representing approximately 1.51 times of the 598,000 Hong Kong Offer Shares initially comprised in pool B.

Under the Hong Kong Public Offering, (i) no application has been rejected due to dishonored payments; (ii) no invalid application has been identified for not having been completed in accordance with the instructions; (iii) 12 multiple applications or suspected multiple applications have been identified and rejected; and (iv) no application for more than 598,000 (being approximately 50% of the 1,196,200 Hong Kong Offer Shares initially available under the Hong Kong Public Offering) has been identified.

As the over-subscription in the Hong Kong Public Offering was less than 15 times, the clawback procedures as disclosed in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus have not been applied. The final number of Hong Kong Offer Shares available under the Hong Kong Public Offering is 1,196,200 Shares, representing approximately 10% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), and being allocated to 2,197 successful applicants under the Hong Kong Public Offering.

The Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the paragraph headed “Basis of Allocation under the Hong Kong Public Offering” in this announcement.

## **INTERNATIONAL OFFERING**

The Offer Shares initially offered under the International Placing have been oversubscribed, representing approximately 2.05 times of the total number of Offer Shares initially available under the International Offering. There is no reallocation of Offer Shares between the Hong Kong Public Offering and the International Offering and the final number of Offer Shares under the International Placing is 10,765,600 Shares, representing approximately 90% of the total number of Offer Shares under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 1,794,200 Offer Shares in the International Offering and there are a total of 140 placees under the International Offering.

A total of 100 placees have been allotted five board lots of Offer Shares or less, representing approximately 71.43% of 140 placees under the International Offering. These placees have been allotted 22,600 Shares in total, representing approximately 0.21% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised). A total of 90 placees have been allotted one board lot of Offer Shares, representing approximately 64.29% of 140 placees under the International Offering. These placees have been allotted 18,000 Shares in total, representing approximately 0.17% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised).

## CORNERSTONE INVESTORS

Based on the Offer Price of HK\$18.00 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) and pursuant to the Cornerstone Investment Agreements as disclosed in the section headed “Cornerstone Investors” in the Prospectus, the number of Offer Shares subscribed for by the Cornerstone Investors is determined as set out below:

Cornerstone Investor	Subscription amount (RMB in million)	Number of Offer Shares <sup>2</sup>	Based on a final Offer Price of HK\$18.00 per Share			
			Assuming the Over-allotment Option is not exercised		Assuming the Over-allotment Option is fully exercised	
			Approximate % of the Offer Shares	Approximate % of the issued share capital	Approximate % of the Offer Shares	Approximate % of the issued share capital
Nanchang Financial	29.70	1,938,800	16.21%	0.81%	14.09%	0.80%
Nanchang Industrial Park	69.30	4,523,000	37.81%	1.89%	32.88%	1.88%
Maccura Biotechnology <sup>1</sup>	49.50	3,231,000	27.01%	1.35%	23.49%	1.34%
Total	148.50	9,692,800	81.03%	4.05%	70.46%	4.02%

*Note:*

1. Maccura Biotechnology is regarded as a close associate of our existing Shareholder, Maccura Biotechnology (USA) LLC, which is a wholly-owned subsidiary of Maccura Biotechnology. We have applied for, and the Stock Exchange has granted us, a waiver from strict compliance with Rule 10.04 and consent under Paragraph 5(2) of Appendix 6 to the Listing Rules in respect of the allocation of Offer Shares to Maccura Biotechnology. For details, please refer to the paragraph headed “International Offering – Placing of International Offer Shares with Consent under Paragraph 5(2) of Placing Guidelines” in this announcement.
2. The actual number of Offer Shares varied from the disclosure in the Prospectus due to the actual exchange rate used for subscription according to the relevant Cornerstone Investment Agreements.

The Cornerstone Placing forms part of the International Offering, and the Cornerstone Investors will not acquire any Offer Shares under the Global Offering other than pursuant to the Cornerstone Investment Agreements. The Offer Shares to be subscribed by the Cornerstone Investors will rank *pari passu* in all respects with the other fully paid Shares in issue following the completion of the Global Offering and for the purpose of Rule 8.08 of the Listing Rules, will be counted towards the public float of our Company.

Immediately following the completion of the Global Offering, the Cornerstone Investors will not become a substantial Shareholder (as defined in the Listing Rules) of our Company and will not have any Board representation in our Company. To the best knowledge of our Company, other than Maccura Biotechnology who is a close associate of our existing Shareholder, each of Cornerstone Investors (and, for Cornerstone Investors who will subscribe for our Offer Shares through a QDII, such QDII) (i) is an Independent Third Party and is not our connected persons and their respective associates (as defined under the Listing Rules), is not existing Shareholders of our Company or their respective close associates; (ii) is not financed by our Company, our subsidiaries, our Directors, chief executive, substantial Shareholders, existing Shareholders or their respective close associates, and (iii) is not accustomed to taking instructions from our Company, our subsidiaries, our Directors, chief executive, substantial Shareholders, existing Shareholders or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in their name or otherwise held by them.

To the extent that any Cornerstone Investor has engaged a QDII to subscribe for the relevant Offer Shares on its behalf, such Cornerstone Investor will procure the QDII to comply with the terms of its Cornerstone Investment Agreement in order to ensure the compliance of such Cornerstone Investor with its obligations under its Cornerstone Investment Agreement.

As confirmed by each of the Cornerstone Investors, there are no side agreements or arrangements between us and the Cornerstone Investors or any benefit, direct or indirect, conferred on the Cornerstone Investors by virtue of or in relation to the Cornerstone Placing. The Cornerstone Investors do not have any preferential rights in the Cornerstone Investment Agreements compared with other public Shareholders, other than a guaranteed allocation of the relevant Offer Shares at the Offer Price.

To the best knowledge of our Company and as confirmed by each Cornerstone Investor, its subscription under the Cornerstone Placing would be financed by its own internal financial resources. Each of the Cornerstone Investors has confirmed that all necessary approvals have been obtained with respect to the Cornerstone Placing, and that no specific approval from any stock exchange (if relevant) or its shareholders is required for the relevant cornerstone investment.

Each of the Cornerstone Investors has agreed that it will not, whether directly or indirectly, at any time during the period of six (6) months from the Listing Date (the “**Lock-up Period**”), (i) dispose of, in any way, any of the Offer Shares they have purchased pursuant to the relevant Cornerstone Investment Agreement (the “**Relevant Shares**”) or any interest in any company or entity holding any Relevant Shares, including any securities convertible into or exchangeable or exercisable for or that represent the right to receive any of the foregoing securities; (ii) agree or contract to or publicly announce any intention to enter into a transaction with a third party for disposal of the Relevant Shares; (iii) allow itself to undergo a change of control (as defined in The Codes on Takeovers and Mergers and Share Buy-backs promulgated by the SFC) at the level of its ultimate beneficial owner; or (iv) enter into or publicly announce the intention to enter into any transactions directly or indirectly with the same economic effect as any aforesaid transaction.

Please refer to the section headed “Cornerstone Investors” in the Prospectus for further details relating to the Cornerstone Investors.

## **PLACING OF INTERNATIONAL OFFER SHARES WITH CONSENT UNDER PARAGRAPH 5(2) OF PLACING GUIDELINES**

Under the International Offering, 3,231,000 Offer Shares, representing approximately 27.01% of the Offer Shares initially available under the Global Offering (assuming the Over-allotment Option is not exercised), were placed to Maccura Biotechnology, which is a close associate of an existing minority Shareholder, Maccura Biotechnology (USA) LLC, within the meaning of Placing Guidelines. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and the consent under paragraphs 5(2) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to Maccura Biotechnology as a cornerstone investor, subject to all the conditions under the consent granted by the Stock Exchange. Immediately following completion of the Global Offering (assuming the Over-allotment Option is not exercised), approximately 1.35% of total issued share capital of the Company will be held by Maccura Biotechnology.

The International Offering is conducted in compliance with the Placing Guidelines. The Directors confirm that save as disclosed above, no International Offer Share has been allocated to the core connected persons of the Company, the Directors, the existing Shareholders or their respective close associates (whether in their own names or through nominees) or any other persons as described in paragraph 5 of the Placing Guidelines. None of the Sole Sponsor, the Sole Global Coordinator, the Joint Bookrunners, the Joint Lead Managers and the Underwriters, their respective affiliate companies, and the connected clients (as defined in the Placing Guidelines) of the lead broker (as defined in the Placing Guidelines) or of any distributors (as defined in the Placing Guidelines) has taken up any Offer Share for its own benefits under the Global Offering.

The Directors confirm that none of the placees under the International Offering was placed more than 10% of the enlarged issued share capital of the Company immediately after completion of the Global Offering. Accordingly, the Directors confirm that none of the placees will become a substantial shareholder of the Company after the completion of the Global Offering, and there will not be any new substantial shareholder of the Company immediately after completion of the Global Offering.

To the best of the knowledge of the Directors, save as disclosed above, (i) none of the Offer Shares subscribed for by the placees or the public has been financed directly or indirectly by any of the Directors, chief executive, Controlling Shareholders, Substantial Shareholders or existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the members of the public who or which have subscribed for the Offer Shares is accustomed to taking instructions from any of the Directors, chief executive, Controlling Shareholders, Substantial Shareholders or existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in their names or otherwise held by them.

## **OVER-ALLOTMENT OPTION**

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Sole Representative on behalf of the International Underwriters, at any time from the Listing Date to Friday, July 15, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 1,794,200 additional Offer Shares, representing approximately 15% of the initial number of Offer Shares to be offered in the Global Offering, at the Offer Price to cover over-allocations in the International Offering, if any.

There has been an over-allocation of 1,794,200 Offer Shares in the International Offering and such over-allocation will be settled by using Shares to be borrowed under the Stock Borrowing Agreement between Infinite Galaxy Health Limited and the Stabilising Manager. Such borrowed Shares will be covered by exercising the Over-allotment Option in full or in part, or by making purchases in the secondary market at prices that do not exceed the Offer Price, or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Company's website at <https://www.megagenomics.cn/> and on the Stock Exchange's website at **www.hkexnews.hk**, respectively.

As of the date of this announcement, the Over-allotment Option has not been exercised.

## LOCK-UP UNDERTAKINGS

Each of the Company, the Controlling Shareholders, the Warranting Shareholders, the Pre-IPO Investors and the Cornerstone Investors has given certain undertakings in relation to the issue or disposal of Shares (the “**Lock-up Undertakings**”). The major terms of the Lock-up Undertakings are set out as follows:

Name	Number of Shares directly held immediately following completion of the Global Offering which are subject to lock-up undertaking upon Listing	Approximate percentage of total number of issued Shares immediately following completion of the Global Offering (before any exercise of the Over allotment Option)	Last day of the lock-up period
<i>Company</i>	N/A	N/A	December 21, 2022 <sup>1</sup>
<i>Controlling Shareholders</i>			
Dr. Yu, YURONG TECHNOLOGY LIMITED, Tianjin Hongzhi Kangjian Management Consulting Partnership (LP) (天津鴻智康健管理諮詢合夥企業(有限合夥))	22,795,135	9.53%	
• First Six-month Period			December 21, 2022 <sup>2</sup>
• Second Six-month Period			June 21, 2023 <sup>3</sup>
Ms. Guo, Infinite Galaxy Health Limited	22,000,000	9.20%	
• First Six-month Period			December 21, 2022 <sup>2</sup>
• Second Six-month Period			June 21, 2023 <sup>3</sup>
Meinian OneHealth, Mei Nian Investment Limited	37,258,932	15.57%	
• First Six-month Period			December 21, 2022 <sup>2</sup>
• Second Six-month Period			June 21, 2023 <sup>3</sup>

Name	Number of Shares directly held immediately following completion of the Global Offering which are subject to lock-up undertaking upon Listing	Approximate percentage of total number of issued Shares immediately following completion of the Global Offering (before any exercise of the Over allotment Option)	Last day of the lock-up period
<b><i>Other Warranting Shareholders<sup>4</sup></i></b>			
Lin Lin <sup>5</sup>	9,975,311	4.17%	
• First Six-month Period			December 21, 2022 <sup>2</sup>
• Second Six-month Period			June 21, 2023 <sup>3</sup>
Huang Yufeng <sup>6</sup>	3,463,131	1.45%	
• First Six-month Period			December 21, 2022 <sup>2</sup>
• Second Six-month Period			June 21, 2023 <sup>3</sup>
<b><i>Pre-IPO Investors<sup>7</sup></i></b>			
Tianjin Shiji Yuneng Enterprise Management Partnership (LP) (天津世紀宇能企業管理合夥企業 (有限合夥))	12,096,203	5.06%	December 21, 2022 <sup>2</sup>
Tianjin Damei Shengjian Enterprise Management Partnership (LP) (天津大美生健企業管理合夥企業 (有限合夥))	11,039,994	4.61%	December 21, 2022 <sup>2</sup>
Sampure Technology Ltd.	6,408,142	2.68%	December 21, 2022 <sup>2</sup>
Maccura Biotechnology (USA) LLC	4,943,642	2.07%	December 21, 2022 <sup>2</sup>
GRteam Global Limited	4,943,642	2.07%	December 21, 2022 <sup>2</sup>

Name	Number of Shares directly held immediately following completion of the Global Offering which are subject to lock-up undertaking upon Listing	Approximate percentage of total number of issued Shares immediately following completion of the Global Offering (before any exercise of the Over allotment Option)	Last day of the lock-up period
Tianjin Fanding Jiayin Enterprise Management Partnership (LP) (天津泛鼎佳因企業管理合夥企業(有限合夥))	4,000,000	1.67%	December 21, 2022 <sup>2</sup>
Tianjin Ruihua Enterprise Management Partnership (LP) (天津瑞華企業管理合夥企業(有限合夥))	3,846,154	1.61%	December 21, 2022 <sup>2</sup>
Tianjin Zhongcai Rongxin Consulting Center (LP) (天津中財榕信諮詢中心(有限合夥))	3,846,154	1.61%	December 21, 2022 <sup>2</sup>
Tianjin Yifeng Enterprise Management Partnership (LP) (天津懿葑企業管理合夥企業(有限合夥))	2,640,004	1.10%	December 21, 2022 <sup>2</sup>
TRUE SOURCE JUNHE HOLDING LTD.	2,471,821	1.03%	December 21, 2022 <sup>2</sup>
ZhenguoD Holding Limited	2,222,200	0.93%	December 21, 2022 <sup>2</sup>
Power Young Incorporated	2,172,907	0.91%	December 21, 2022 <sup>2</sup>
Weber Education Group CORP	2,000,000	0.84%	December 21, 2022 <sup>2</sup>
CindyHu TECHNOLOGY LTD.	1,977,457	0.83%	December 21, 2022 <sup>2</sup>
Sancost China Technology Co., Ltd	1,799,811	0.75%	December 21, 2022 <sup>2</sup>

Name	Number of Shares directly held immediately following completion of the Global Offering which are subject to lock-up undertaking upon Listing	Approximate percentage of total number of issued Shares immediately following completion of the Global Offering (before any exercise of the Over allotment Option)	Last day of the lock-up period
Tianjin Yixin Enterprise Management Partnership (LP) (天津易新企業管理合夥企業(有限合夥))	1,647,881	0.69%	December 21, 2022 <sup>2</sup>
SNOW MOUTAIN CAPITAL LIMITED	1,481,478	0.62%	December 21, 2022 <sup>2</sup>
Ninge Technology Limited	1,400,007	0.59%	December 21, 2022 <sup>2</sup>
New Wave Song Corporation	1,111,199	0.46%	December 21, 2022 <sup>2</sup>
ZHOUQUAN HOLDING LIMITED	370,394	0.15%	December 21, 2022 <sup>2</sup>
<b><i>Cornerstone Investors<sup>8</sup></i></b>			
Nanchang Financial	1,938,800	0.81%	December 21, 2022 <sup>2</sup>
Nanchang Industrial Park	4,523,000	1.89%	December 21, 2022 <sup>2</sup>
Maccura Biotechnology	3,231,000	1.35%	December 21, 2022 <sup>2</sup>

*Note:*

1. The Company may not allot or issue Shares prior to the indicated date except otherwise permitted by the Listing Rules and the Stock Exchange.
2. After the date indicated, the respective lock-up undertaking shall no longer apply and the relevant Shareholder shall be entitled to deal in the Shares without being subject to the same.
3. Dispose of or transfer these Shares may be allowed provided that any of the Controlling Shareholders will not cease to be a controlling shareholder (as defined in the Listing Rules) of the Company during the Second Six-Month Period.
4. Under the Hong Kong Underwriting Agreement, without prior written consent of the Sole Representative (for itself and on behalf of the Underwriters) and the Sole Sponsor, the Warranting Shareholders are subject to, among others, (i) certain restrictions on disposal of Shares during the First Six-Month Period; and (ii) certain restrictions on disposal of Shares during the Second Six-Month Period if any of the Controlling Shareholders would cease to be a controlling shareholder (as defined in the Listing Rules). For further details, please refer to “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement” in the Prospectus.
5. Ms. Lin is deemed to be interested in the Shares held by LINLIN DJK HOLDING LTD. under the SFO, as LINLIN DJK HOLDING LTD. is wholly owned by Ms. Lin.
6. Mr. Huang is deemed to be interested in the Shares held by Main Sunflower Technology Limited under the SFO, as Main Sunflower Technology Limited is held as to 54.84% by Mr. Huang.
7. For further details, please refer to “History, Reorganization and Group Structure – Pre-IPO Investments – Lock-up and Public Float” in the Prospectus.
8. For further details, please refer to “Cornerstone Investors – Restrictions on Disposals By the Cornerstone Investors” in the Prospectus.

## BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to satisfaction of the conditions set out in “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus, 9,206 valid applications made by the public through the **HK eIPO White Form** service or the **CCASS EIPO** service will be conditionally allocated on the basis set out below:

Pool A			Approximate percentage allotted of the total number of shares applied for
Number of shares applied for	Number of valid applications	Basis of allocation/ballot	
200	5,253	526 out of 5,253 applicants to receive 200 shares	10.01%
400	1,575	298 out of 1,575 applicants to receive 200 shares	9.46%
600	426	116 out of 426 applicants to receive 200 shares	9.08%
800	257	88 out of 257 applicants to receive 200 shares	8.56%
1,000	414	166 out of 414 applicants to receive 200 shares	8.02%
1,200	88	40 out of 88 applicants to receive 200 shares	7.58%
1,400	55	28 out of 55 applicants to receive 200 shares	7.27%
1,600	61	34 out of 61 applicants to receive 200 shares	6.97%
1,800	46	28 out of 46 applicants to receive 200 shares	6.76%
2,000	434	287 out of 434 applicants to receive 200 shares	6.61%
3,000	99	88 out of 99 applicants to receive 200 shares	5.93%
4,000	123	200 shares plus 20 out of 123 applicants to receive an additional 200 shares	5.81%
5,000	78	200 shares plus 30 out of 78 applicants to receive an additional 200 shares	5.54%
6,000	46	200 shares plus 28 out of 46 applicants to receive an additional 200 shares	5.36%
7,000	19	200 shares plus 15 out of 19 applicants to receive an additional 200 shares	5.11%
8,000	25	200 shares plus 22 out of 25 applicants to receive an additional 200 shares	4.70%
9,000	21	200 shares plus 20 out of 21 applicants to receive an additional 200 shares	4.34%
10,000	107	400 shares	4.00%
20,000	32	600 shares plus 23 out of 32 applicants to receive an additional 200 shares	3.72%
30,000	12	1,000 shares plus 6 out of 12 applicants to receive an additional 200 shares	3.67%
40,000	10	1,400 shares plus 2 out of 10 applicants to receive an additional 200 shares	3.60%
50,000	5	1,600 shares plus 4 out of 5 applicants to receive an additional 200 shares	3.52%
60,000	2	2,000 shares plus 1 out of 2 applicants to receive an additional 200 shares	3.50%

<b>Number of shares applied for</b>	<b>Number of valid applications</b>	<b>Basis of allocation/ballot</b>	<b>Approximate percentage allotted of the total number of shares applied for</b>
70,000	3	2,400 shares	3.43%
90,000	1	3,000 shares	3.33%
100,000	5	3,000 shares plus 3 out of 5 applicants to receive an additional 200 shares	3.12%
200,000	6	6,000 shares	3.00%
<b>Total</b>	<b>9,203</b>		<b>Total number of Pool A successful applicants: 2,194</b>

### **Pool B**

<b>Number of shares applied for</b>	<b>Number of valid applications</b>	<b>Basis of allocation/ballot</b>	<b>Approximate percentage allotted of the total number of shares applied for</b>
300,000	3	199,200 shares plus 2 out of 3 applicants to receive an additional 200 shares	66.44%
<b>Total</b>	<b>3</b>		<b>Total number of Pool B successful applicants: 3</b>

The final number of Hong Kong Offer Shares available under the Hong Kong Public Offering is 1,196,200 Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

### **Results of Allocations**

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be available at the times and date and in the manner specified below:

- in the announcement to be posted on the Company's website at <https://www.megagenomics.cn/> and the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk) by no later than 9:00 a.m. on Tuesday, June 21, 2022;
- from the “IPO Results” function in the **IPO App** and the designated results of allocations website at [www.tricor.com.hk/ipo/result](http://www.tricor.com.hk/ipo/result) or [www.hkeipo.hk/IPOResult](http://www.hkeipo.hk/IPOResult) with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Tuesday, June 21, 2022, to 12:00 midnight on Monday, June 27, 2022;
- from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Tuesday, June 21, 2022, to Friday, June 24, 2022 on a business day.

This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **HK eIPO White Form**” refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **electronic application instructions** to HKSCC via CCASS” are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **HK eIPO White Form**” and “Results of Applications Made by Giving **electronic application instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

## SHAREHOLDING CONCENTRATION ANALYSIS

Set out below is a summary of the allotment results under the Global Offering:

- the number of Offer Shares subscribed for by the top 1, 5, 10 and 25 placees under the International Offering, their subscription percentages in the International Offering, their subscription percentages in the International Offering and the Global Offering, and their shareholding percentages upon Listing are as follows:

Placees	Subscription Listing <sup>Note</sup>	Subscription			% of total issued share capital upon Listing		
		Aggregate Number of Shares held upon allotment	Subscription as % of International Offering (assuming no exercise of the Over- held upon allotment	Subscription as % of International Offering (assuming the Over- allotment Option is exercised	Subscription as % of total Offer Shares (assuming no exercise of the Over- allotment Option is exercised	% of total issued share capital upon Listing (assuming the Over- allotment Option is exercised	
			Subscription as % of International Offering (assuming the Over- allotment Option is exercised in full)	Subscription as % of Offer Shares (assuming the Over- allotment Option is exercised in full)	% of total issued share capital upon Listing (assuming the Over- allotment Option is exercised in full)		
Top 1	6,461,800	6,461,800	60.02%	51.45%	54.02%	46.97%	2.70% 2.68%
Top 5	11,167,000	16,110,642	103.73%	88.91%	93.36%	81.18%	6.73% 6.68%
Top 10	11,901,400	16,845,042	110.55%	94.76%	99.50%	86.52%	7.04% 6.99%
Top 25	12,448,200	17,391,842	115.63%	99.11%	104.07%	90.49%	7.27% 7.22%

*Note:* As Maccura Biotechnology’s close associate is an existing shareholder of the Company and Maccura Biotechnology subscribed 3,231,000 Shares as a cornerstone investor, we aggregate the number of shares held by Maccura Biotechnology and its close associate and treat them as one placee under this analysis. Nanchang Financial is a wholly-owned subsidiary of Nanchang Industry Holding Group Co.,Ltd (南昌市產業投資集團有限公司) (previously known as Nanchang Industrial Holdings Group Co., Ltd. (南昌工業控股集團有限公司)), a company owned as to 90% by the People’ Government of Nanchang Municipality (南昌市人民政府), and Nanchang Industrial Park is owned as to approximately (i) 69.9% by Nanchang Guojin Industrial Investment Co., Ltd. (南昌市國金工業投資有限公司), (ii) 29.9% by Nanchang Industrial Control Investment Fund Management Co., Ltd. (南昌工控投資基金管理有限公司), both of which are wholly owned by Nanchang Industry Holding Group Co.,Ltd. As both of Nanchang Financial and Nanchang Industrial Park are indirectly

held by the People' Government of Nanchang Municipality, we aggregate the number of shares held by Nanchang Financial and Nanchang Industrial Park and treat them as one placee under this analysis. For further details regarding the background of Maccura Biotechnology, Nanchang Financial and Nanchang Industrial Park, please refer to "Cornerstone Investors – The Cornerstone Investors" in the Prospectus. Therefore the number of Offer Shares subscribed for the top 5, 10 and 25 placees under the International Offering and the aggregate number of Shares held by them upon Listing are different.

- the number of Offer Shares subscribed for by the top 1, 5, 10 and 25 Shareholders upon Listing, the number of Offer Shares to be directly held by them upon Listing, their subscription percentages in the International Offering and the Global Offering, and their shareholding percentages upon Listing are as follows:

Shareholders	Subscription Listing <sup>Note</sup>	Subscription as % of International Offering International Offering Aggregate Number of Shares held upon listing		Subscription as % of total Offer Shares (assuming the Over- allotment Option is exercised in full)		Subscription as % of Offer Shares (assuming no exercise of the Over- allotment Option is exercised in full)		% of total issued share capital upon listing (assuming the Over- allotment Option is exercised in full)
		Subscription as % of International Offering (assuming no exercise of the Over- allotment Option)	Subscription as % of total Offer Shares (assuming the Over- allotment Option is exercised in full)	Subscription as % of Offer Shares (assuming no exercise of the Over- allotment Option is exercised in full)	% of total issued share capital upon listing (assuming the Over- allotment Option is exercised in full)			
Top 1	0	37,258,932	0.00%	0.00%	0.00%	0.00%	15.57%	15.46%
Top 5	0	121,422,270	0.00%	0.00%	0.00%	0.00%	50.75%	50.38%
Top 10	9,692,800	167,594,410	90.03%	77.17%	81.03%	70.46%	70.05%	69.53%
Top 25	9,692,800	224,347,724	90.03%	77.17%	81.03%	70.46%	93.78%	93.08%

*Note:* We aggregate the number of shares held by different entities which were owned by the same beneficial owner and treat such entities as one shareholder under this analysis.

**In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded and should exercise extreme caution when dealing in the Shares.**